Search peptides, terms, sources/
Metabolic and incretin

Tirzepatide

Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials4 human trials · 1 lab (in-vitro)

What is Tirzepatide?

Tirzepatide is a synthetic peptide that acts on both the GIP and GLP-1 receptors, studied in type 2 diabetes, weight management and obstructive sleep apnoea. In the UK it is a prescription-only medicine licensed for specific indications. The research includes large placebo-controlled randomised trials.

Further research covers heart failure with preserved ejection fraction in people with obesity.

Class
Dual GIP/GLP-1 receptor co-agonist, Incretin mimetic
Origin
Analogue / modified
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Tirzepatide work?

Tirzepatide activates two receptors, for the gut hormones GIP and GLP-1. Both help the body release insulin when blood sugar is high, and GLP-1 also slows stomach emptying and lowers appetite. Lab work suggests the two actions add together, but this has not been tested directly in people.

The mechanism in more detail

Tirzepatide is a 39-amino-acid synthetic peptide built on the native GIP sequence, engineered with a fatty-acid moiety that binds albumin and extends its half-life. It has been shown in receptor-pharmacology studies to bind the GIP receptor with an affinity comparable to native GIP, while its affinity for the GLP-1 receptor is reported as considerably weaker than native GLP-1, a pattern described in the literature as “imbalanced” or “biased” dual agonism that favours cAMP-generating signalling over receptor internalisation at the GLP-1 receptor.

GIP receptor activation has been shown in preclinical and receptor-assay work to enhance pancreatic beta-cell function and insulin sensitivity. GLP-1 receptor activation is separately associated with suppressed glucagon secretion, delayed gastric emptying, and reduced appetite. Preclinical research suggests these two mechanisms act synergistically, producing greater weight reduction than GLP-1 receptor agonism alone, though this synergy claim rests on in-vitro and animal pharmacology rather than a head-to-head mechanistic trial in humans.

Mechanisms and targets

Appetite/satiety regulationBiased/imbalanced receptor agonismDual GIP/GLP-1 receptor co-agonismIncretin-hormone signallingGIP receptor (GIPR)GLP-1 receptor (GLP-1R)

Classification and structure

Names
Tirzepatide; Mounjaro (diabetes/weight-management brand); Zepbound (US weight-management brand, not the UK brand name); research code LY3298176
Class
Dual GIP/GLP-1 receptor co-agonist Incretin mimetic
Origin
Analogue / modified
Structure
39-amino-acid synthetic peptide based on the native GIP sequence backbone, engineered with a C20 fatty di-acid moiety for albumin binding and an extended half-life.
Routes used in the research
Subcutaneous injection in the SURMOUNT, SURPASS and SURMOUNT-OSA trials.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Tirzepatide has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
10220

The SURMOUNT-1 obesity trial Strong

In adults with obesity or overweight without diabetes, tirzepatide produced substantial, dose-dependent weight loss over 72 weeks versus placebo (SURMOUNT-1 phase 3 trial).

Study type
Human trial
Population
Adults with BMI 30 or above (or 27 or above with 1 or more weight-related comorbidity), without diabetes; phase 3, double-blind, placebo-controlled, multicentre.
Source
1 Jastreboff et al., 2022

Limitation: Sponsor-funded (Eli Lilly); dose-dependent gastrointestinal adverse events are the main tolerability constraint reported alongside efficacy.

SURMOUNT-5 head-to-head comparison Moderate

In a head-to-head phase 3b trial (SURMOUNT-5), tirzepatide produced greater weight loss than semaglutide over 72 weeks in adults with obesity: -20.2% against -13.7% (p<0.001).

Study type
Human trial
Population
751 adults with obesity, without type 2 diabetes; open-label, direct active-comparator design, randomised 1:1 to the maximum tolerated dose of each medicine.
Source
2 Aronne et al., 2025

Limitation: Sponsor-funded (Eli Lilly), a head-to-head comparison with another company's medicine.

Limitations in full

Sponsor-funded (Eli Lilly), a head-to-head comparison with another company's medicine. Open-label design.

Obstructive sleep apnoea trial Strong

In adults with obesity and moderate-to-severe obstructive sleep apnoea, tirzepatide reduced the apnoea-hypopnoea index by approximately 50.7 to 58.7% and reduced hsCRP (a cardiometabolic risk marker) by roughly 40 to 50%, alongside improvements in patient-reported outcomes (SURMOUNT-OSA).

Study type
Human trial
Population
Two 52-week, randomised, double-blind, placebo-controlled phase 3 studies in adults with obesity and moderate to severe obstructive sleep apnoea.
Source
3 Nature Medicine, 2025

Limitation: Obstructive sleep apnoea-specific population; AHI reduction is a respiratory/cardiometabolic surrogate marker, not itself a hard cardiovascular-event outcome.

The SUMMIT heart-failure trial Moderate

In a phase 3 trial (SUMMIT) in 731 people with heart failure with preserved ejection fraction and obesity, a composite of cardiovascular death or a worsening heart-failure event occurred in 9.9% on tirzepatide and 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95), over a median follow-up of 104 weeks. Symptom scores also improved versus placebo.

Study type
Human trial
Population
Adults with heart failure with preserved ejection fraction and obesity.
Source
4 Packer et al., 2025

Limitation: Sponsor-funded (Eli Lilly).

Limitations in full

Sponsor-funded (Eli Lilly). Single trial in one population: heart failure with preserved ejection fraction and obesity.

Dual GIP/GLP-1 receptor mechanism Preliminary

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist showing imbalanced/biased agonism, with high-affinity, GIP-like engagement at the GIP receptor, and biased, cAMP-favouring signalling at the GLP-1 receptor with weaker receptor internalisation than native GLP-1.

Study type
Lab (in-vitro)
Population
Cell-based receptor pharmacology assays (primary islets, recombinant receptor systems).
Source
5 Willard et al., 2020

Limitation: In-vitro data; translational relevance is supported indirectly by the clinical efficacy findings above, but this specific mechanistic claim was not itself tested in humans.

What safety findings have been reported?

3 safety findings are recorded for Tirzepatide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

SURMOUNT-4 gastrointestinal events

Gastrointestinal adverse events (nausea, diarrhoea, constipation, vomiting) are the most common adverse reactions with tirzepatide; in the SURMOUNT-4 randomised trial, nausea occurred in 35.5%, diarrhoea in 21.1%, constipation in 20.7%, and vomiting in 16.3% of participants, mostly mild to moderate.

Source
6 Zeng et al., 2023

Pancreatitis and biliary risk

A systematic review and meta-analysis found acute pancreatitis reported at a pooled proportion of approximately 0.32 to 0.39% across tirzepatide dose groups in type 2 diabetes and obesity populations, described by the reviewers as not indicating an elevated pancreatitis risk versus comparators. The same body of evidence flagged increased gallbladder/biliary tract disease risk in some analyses as warranting continued clinical attention.

Source
6 Zeng et al., 2023

MHRA class-wide flags

Gastrointestinal effects, rare acute pancreatitis (including rare fatal reports across the GLP-1/GIP-agonist class), and counterfeit-product risks are flagged by the MHRA as a class-wide concern applicable to Mounjaro alongside other licensed GLP-1/GIP medicines. The MHRA has explicitly stated that safety and effectiveness outside the licensed indications, such as weight loss in people who are not obese or overweight, has not been assessed.

Source
7 MHRA, 2026

What is Tirzepatide's UK regulatory status?

Marketing authorisation
Licensed: MHRA marketing authorisation granted for type 2 diabetes (September/October 2022) and subsequently extended to weight management (8 November 2023).
Prescription status
Prescription-only medicine (POM).
Medicine class
Licensed medicinal product.
MHRA position
MHRA-authorised for type 2 diabetes (as monotherapy where metformin is inappropriate, or as add-on therapy) and for weight management (adjunct to reduced-calorie diet and increased physical activity) in adults with BMI 30 or above, or BMI 27 to under 30 with at least one weight-related comorbidity (for example hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes). Tirzepatide is described in MHRA/NHS guidance as one of only a small number of GLP-1/GIP-class products licensed for weight management in the UK.
Authorised use
Type 2 diabetes mellitus (adults, adolescents and children aged 10 and over); weight management in adults. Heart failure with preserved ejection fraction and obstructive sleep apnoea are research findings, not separate licensed indications (UK product information on the eMC, checked 14 November 2026).
Research use
Not applicable in the unlicensed research-chemical sense. Tirzepatide is a licensed medicine.
Other restrictions
NICE technology appraisal TA1026 (published 23 December 2024) recommends tirzepatide for managing overweight and obesity, and, unlike earlier NICE guidance on semaglutide/liraglutide, states tirzepatide can be used in primary care or specialist weight-management services. NICE guidance also reduces the BMI threshold by approximately 2.5 kg/m2 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean ethnic backgrounds. MHRA has separately warned about use outside licensed indications and about counterfeit/falsified product circulation.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

8 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2206038 · Original ↗
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 393(1):26-36Human clinical trial, RCT · DOI 10.1056/NEJMoa2416394 · PMID 40353578 · Original ↗
  3. Nature Medicine (2025). Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nature MedicineHuman clinical trial, RCT · Original ↗
  4. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine, 392(5):427-437Human clinical trial, RCT · DOI 10.1056/NEJMoa2410027 · PMID 39555826 · Original ↗
  5. Willard FS, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI InsightIn-vitro · DOI 10.1172/jci.insight.140532 · Original ↗
  6. Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology, 14:1214334Human clinical trial, RCT · DOI 10.3389/fendo.2023.1214334 · PMID 37908750 · Original ↗
  7. MHRA (UK government body) (2026). GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UKGovernment guidance · Original ↗
  8. eMC (2026). Tirzepatide injection: Summary of Product Characteristics, eMC. electronic Medicines Compendium (eMC) · Original ↗

Questions about Tirzepatide

What is Tirzepatide?

Tirzepatide is a synthetic peptide that acts on both the GIP and GLP-1 receptors, studied in type 2 diabetes, weight management and obstructive sleep apnoea. In the UK it is a prescription-only medicine licensed for specific indications. The research includes large placebo-controlled randomised trials. Read what it is.

Is Tirzepatide licensed in the UK?

PeptGuru records Tirzepatide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Tirzepatide show?

PeptGuru records 5 research findings for Tirzepatide: 4 from human trials and 1 from a lab (in-vitro) study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Tirzepatide?

3 safety findings are recorded, including: SURMOUNT-4 gastrointestinal events; pancreatitis and biliary risk; MHRA class-wide flags. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Tirzepatide?

All 8 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · The SUMMIT trial reference now carries its DOI and PubMed ID (Packer et al., NEJM 2025).
  • Evidence update · SURMOUNT-5 and SUMMIT figures checked against the primary papers and corrected.
  • Regulatory update · UK status re-checked against the official product information; no change to the licensed uses.

How findings are graded: the grading method. All changes.

  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK

Compare Tirzepatide with Liraglutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.